Tissue-type plasminogen activator therapy versus primary coronary angioplasty: Impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction

被引:43
|
作者
Agati, L
Voci, P
Hickle, P
Vizza, DC
Autore, C
Fedele, F
Feinstein, SB
Dagianti, A
机构
[1] Univ Roma La Sapienza, Dept Cardiol & Cardiac Surg, I-00161 Rome, Italy
[2] Univ Illinois, Dept Cardiol, Chicago, IL USA
关键词
D O I
10.1016/S0735-1097(97)00487-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study sought to compare the impact of primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) on 1-month infarct size and microvascular perfusion. Background. The effect of the reperfusion strategies of primary coronary angioplasty and thrombolytic therapy on microvascular integrity still remains to be determined. Methods. Sixty two consecutive patients with a first AMI, undergoing intravenous tissue-type plasminogen activator (t-PA) therapy (32 patients, Group I) or primary angioplasty (30 patients, Group II), were studied. Only patients with 1-month Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 were selected for the study, Patients in whom primary angioplasty was unsuccessful or those with clinical evidence of failed reperfusion were excluded. Microvascular perfusion was assessed at 1 month by intracoronary injection of sonicated microbubbles. Contrast score index (CSI) and wall motion score index (WMSI) were derived using qualitative methods. Results. At baseline there were no significant differences between groups for age, risk factors, time to hospital presentation, Killip class on admission, prevalence of multivessel disease or anterior infarct site, infarct area extension before reperfusion, peak creatine kinase levels and postinfarction treatment. Conversely, significant differences between groups were found at follow-up for percent residual infarct related-artery (IRA) stenosis (70 +/- 12 vs 36 +/- 14 [mean +/- SD], p = 0.0001), CSI (1.02 +/- 0.4 vs. 1.49 +/- 0.5, p = 0.0003) and WMSI (1.67 +/- 0.3 vs. 1.45 +/- 0.3, p = 0.015). In particular, in the subset of patients with TIMI grade 3 flow, a perfusion defect occurred in one or more segments subtended by the IRA in 72% of Group I versus 31% of Group II patients (p < 0.00001) and in 27% of Group I versus 8% of Group II segments (p < 0.00001), Conclusions. The present study shows, in a highly selected cohort with successful IRA recanalization, that primary angioplasty is more effective than thrombolysis in preserving microvascular flow and preventing extension of myocardial damage at 1-month after AMI. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:338 / 343
页数:6
相关论文
共 50 条
  • [21] Preceding thrombolysis with low-dose mutant tissue-type plasminogen activator followed by coronary angioplasty in acute myocardial infarction: PLANET trial
    Tsurumi, Yukio
    Ishii, Yasuhiro
    Ogawa, Hiroshi
    Koyanagi, Ryo
    Hagiwara, Nobuhisa
    Kasanuki, Hiroshi
    CIRCULATION, 2006, 114 (18) : 598 - 598
  • [22] Tissue level perfusion after primary or rescue coronary angioplasty in acute myocardial infarction: A myocardial contrast echocardiography study
    Agati, L
    Iacoboni, C
    De Maio, F
    Funaro, S
    Madonna, M
    Celani, F
    Adorisio, R
    Benedetti, G
    Fedele, F
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 434A - 434A
  • [23] Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapy
    Molnar, C
    Buratti, T
    Wiedermann, CJ
    Tilg, H
    EUROPEAN CYTOKINE NETWORK, 2000, 11 (01) : 87 - 90
  • [24] A Randomized Comparison Study of Recombinant Staphylokinase versus Recombinant Tissue-Type Tissue Plasminogen Activator for Safety and Coronary Artery Patency in Patients with Acute Myocardial Infarction
    Fu Xianghua
    Sun Jiaan
    Zhang Jing
    Fan Weize
    CIRCULATION, 2010, 122 (02) : E163 - E163
  • [25] LIMITATION OF MYOCARDIAL-INFARCTION BY EARLY INFUSION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OROURKE, M
    BARON, D
    KEOGH, A
    KELLY, R
    NELSON, G
    BARNES, C
    RAFTOS, J
    GRAHAM, K
    HILLMAN, K
    NEWMAN, H
    HEALEY, J
    WOOLRIDGE, J
    RIVERS, J
    WHITE, H
    WHITLOCK, R
    NORRIS, R
    CIRCULATION, 1988, 77 (06) : 1311 - 1315
  • [26] Effects of intracoronary tissue-type plasminogen activator treatment in Kawasaki disease and acute myocardial infarction
    Nakagawa, M
    Watanabe, N
    Okuno, M
    Okamoto, N
    Fujino, H
    CARDIOLOGY, 2000, 94 (01) : 52 - 57
  • [27] THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION - POTENTIALS AND PITFALLS
    JAFFE, AS
    SOBEL, BE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 255 (02): : 237 - 239
  • [28] RANDOMIZED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL-INFARCTION
    ERBEL, R
    CIRCULATION, 1985, 72 (04) : 223 - 223
  • [29] EFFECTS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX ON MORTALITY IN ACUTE MYOCARDIAL-INFARCTION
    HELD, PH
    TEO, KK
    YUSUF, S
    CIRCULATION, 1990, 82 (05) : 1668 - 1674
  • [30] EFFECTS OF LATE ADMINISTRATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR ON LEFT-VENTRICULAR REMODELING AND FUNCTION AFTER MYOCARDIAL-INFARCTION
    BONADUCE, D
    PETRETTA, M
    VILLARI, B
    BREGLIO, R
    CONFORTI, G
    MONTEMURRO, MV
    LANZILLO, T
    MORGANO, G
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (07) : 1561 - 1568